Monoclonal Antibody Therapy in Parkinson's Disease - The End?
N Engl J Med
2022 Aug 4;387(5):466-467.
From Translational Health Sciences, Bristol Medical School, University of Bristol, and the Movement Disorders Group, Bristol Brain Centre, Southmead Hospital, North Bristol NHS Trust - both in Bristol, United Kingdom.
No abstract available
Antibodies, Monoclonal* / therapeutic use
Parkinson Disease* / drug therapy